Approximately 121,000 bariatric surgical procedures are performed annually, and salutary effects include a reduction in cardiovascular morbidity and mortality, risk factor modification, and improvement in sympathovagal tone. There are anecdotal accounts of unexplained sinus bradycardia (SB) after significant weight loss but no systematic studies have been conducted. The purpose of this study was to determine the frequency of incident SB, its timing, and association with weight loss, clinical characteristics, and predictors. We evaluated various clinical characteristics including resting heart rate, blood pressure, body mass index (BMI), heart rate reserve (HRR), basal metabolic rate, and exercise regimen in 151 consecutive patients who underwent bariatric surgery. Multiple logistic regression analysis was performed to determine predictors of SB. Twenty-five of 137 patients (18%) experienced postoperative SB. Patients with SB had significantly greater reduction in BMI than those without bradycardia (35 ± 9.6% and 25.7 ± 13%, respectively, p = 0.002). HRR was significantly greater in patients with SB (116 ± 14 beats/min) compared with those without bradycardia (105 ± 14 beats/min, p = 0.007). Multiple logistic regression analysis revealed that the odds of developing SB were 1.96 and 1.91 and associated with the percent decrease in BMI (95% confidence interval 1.3 to 3.0, p = 0.002) or increase in HRR (95% confidence interval 1.28 to 2.85, p = 0.002), respectively. In conclusion, SB occurred 14 ± 11 months postoperatively and its predictors were the percent reduction in BMI or increase in HRR.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.amjcard.2013.11.069 | DOI Listing |
Eur Heart J Case Rep
January 2025
Department of Cardiology, Hyogo Prefectural Awaji Medical Center, Sumoto, Japan.
Background: Atrial infarction is a complication of myocardial infarction with ventricular infarction; however, isolated atrial infarction (IAI) has rarely been reported. Herein, we report a case of IAI associated with sick sinus syndrome and atrial fibrillation (AF).
Case Summary: An 83-year-old woman was brought to the emergency department with a complaint of general malaise.
Indian J Crit Care Med
January 2025
Clinical Research Associate, Zuventus Healthcare Limited, Mumbai, Maharashtra, India.
Aim And Background: To assess the efficacy and safety of Ibutilide infusion for cardioversion of atrial fibrillation (AF) or flutter (AFL) to sinus rhythm.
Materials And Methods: This open-label, multicenter phase IV study was conducted at six sites across India. The study enrolled 120 patients (108 with AF, 12 with AFL), each receiving up to two, 10-minute intravenous doses of 1.
Eur Heart J Case Rep
January 2025
Department of Cardiology, Edgardo Rebagliati Martins National Hospital, Avenida Edgardo Rebagliati 490, Jesús María, Lima 15072, Perú.
Background: This case report highlights the conduction disorder anomalies associated with dengue infection, particularly bradyarrhythmias due to dysfunction of the sinus node and atrioventricular node, which may require cardiac stimulation such as pacemaker implantation. This case emphasizes the importance of continuous monitoring and the use of additional diagnostic techniques to detect complications in a timely manner.
Case Summary: A 31-year-old male patient was admitted to our institution with symptoms of dyspnoea, orthopnoea, and severe bradycardia.
Eur Heart J
December 2024
Department of Cardiology, IRCCS Istituto Auxologico Italiano, Faint and Fall Research Centre, S. Luca Hospital, Piazzale Brescia 20, Milano 20149, Italy.
Background And Aims: Identifying the haemodynamic mechanism of autonomic syncope is the essential pre-requisite for effective and personalized therapy aimed at preventing recurrences. The present study assessed the diagnostic efficacy of a two-step assessment.
Methods: Multicentre prospective, cross-sectional, observational study.
BMJ Open Gastroenterol
January 2025
Inflammatory Bowel Disease Center and Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Objective: Etrasimod is an oral, once-daily, selective sphingosine 1-phosphate (S1P) receptor modulator for the treatment of moderately to severely active ulcerative colitis (UC). S1P receptor expression on cardiac cells is involved in cardiac conduction. We report cardiovascular treatment-emergent adverse events (TEAEs) associated with S1P receptor modulators and other cardiovascular events in the etrasimod UC clinical programme.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!